Cancer Immunotherapy Market Research 2024-2032: Personalized Cancer Vaccines and CAR T Cell Therapy Revolutionize Immunotherapy
07 oct. 2024 07h18 HE
|
Research and Markets
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report, Forecast by Products, Application, End Users, Countries and Company Analysis, 2024-2032" report has been added to ...
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
04 oct. 2024 10h31 HE
|
Compass Therapeutics
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
04 oct. 2024 09h00 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
01 oct. 2024 08h00 HE
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Neuroendocrine Tumors (NETs) Market Research 2024-2030 with Analyst Recommendations - Establishment of Specialist Therapeutic Centers / Organize Campaigns to Raise Awareness
01 oct. 2024 06h48 HE
|
Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of...
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
30 sept. 2024 08h00 HE
|
Calidi Biotherapeutics, Inc
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
30 sept. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
Multiple Myeloma Therapeutics Market to hit USD 44.2 billion by 2032, says Global Market Insights Inc.
30 sept. 2024 02h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Multiple Myeloma Therapeutics Market size was at approximately USD 25.4 billion in 2023 and will grow at 6.4% CAGR from 2024 to 2032,...
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
20 sept. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
19 sept. 2024 09h41 HE
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...